Gilead Sciences Q1 FY2026 Earnings Call Summary
GILD
NASDAQ
Healthcare
📅 2026-05-07
⏱ ~60 sec read
🟡 Neutral
⏱️ 60-Second Brief
Gilead Sciences · Q1 FY2026
Stock Next Day
▼ 1.96%
$134.06 → $131.43
Revenue
$6.96B
EPS
$1.06
AI Sentiment
🟡 Neutral
While core product sales showed robust growth and revenue gu…
📌 Bottom Line:
Gilead Sciences reported a 4% increase in total revenues to $6.96 billion for the first quarter of 2026, driven by strong performance in its core HIV and oncology segments. However, the company significantly lowered its …
🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy.
·
⚠️ Not financial advice. For informational purposes only.
Full Disclaimer →
📋 TL;DR — What Happened
Gilead Sciences reported a 4% increase in total revenues to $6.96 billion for the first quarter of 2026, driven by strong performance in its core HIV and oncology segments. However, the company significantly lowered its full-year earnings per share guidance due to substantial acquired in-process research and development (IPR&D) charges from recent strategic acquisitions.
📊 Key Financial Metrics
Revenue
$6.96B
EPS (Diluted)
$1.06
YoY Revenue Growth
4%
Gross Margin
79.2%
Net Income
$2.021B
AI Sentiment
🟡 Neutral
While core product sales showed robust growth and revenue guidance was raised, the significant reduction in full-year EPS guidance due to substantial acquisition-related charges creates a mixed outlook for investors.
✅ What Went Well
Strong Core Business Performance: Product sales excluding Veklury demonstrated robust growth, increasing 8% year-over-year to $6.8 billion, indicating healthy demand across Gilead's primary therapeutic areas. This growth was driven by key products in HIV and oncology, showcasing the underlying strength of the company's portfolio.
Dominant HIV Franchise Growth: The HIV product portfolio delivered exceptional results, with sales climbing 10% to $5.0 billion. This was largely propelled by the continued success of Biktarvy, which grew 7% to $3.4 billion, and a remarkable 38% increase in Descovy sales to $807 million, underscoring Gilead's leadership in HIV treatment and prevention.
Accelerating Oncology Momentum: Trodelvy, a key oncology asset, saw its sales surge by 37% to $402 million. This significant increase reflects strong market adoption and expanding use in various cancer indications, positioning Trodelvy as a crucial growth engine for Gilead's burgeoning oncology pipeline.
Improved Gross Margin: The company reported an improved product gross margin of 79.2% for the quarter, up from 76.7% in the same period last year. This enhancement was primarily attributed to the expiration of a royalty-related obligation and a favorable shift in product mix, contributing positively to overall profitability.
Raised Full-Year Revenue Guidance: Management raised its full-year 2026 revenue guidance, signaling confidence in the continued strong performance of its product portfolio and market demand, despite the anticipated impacts on EPS from strategic investments.
⚠️ Concerns & Risks
Significant EPS Guidance Reduction: The most notable concern is the drastic reduction in full-year 2026 GAAP and non-GAAP diluted earnings per share guidance, lowered by approximately $9.50. This substantial revision is primarily due to an anticipated $11.5 billion in acquired IPR&D charges and financing costs associated with recent strategic acquisitions, which will heavily impact short-term profitability.
Declining Veklury Sales: Sales of Veklury, Gilead's COVID-19 treatment, plummeted 52% year-over-year to $144 million. This sharp decline reflects the decreasing global demand for COVID-19 therapies as the pandemic wanes, indicating a diminishing revenue stream from this once-significant product.
Competitive Headwinds in Cell Therapy: Cell Therapy product sales decreased 12% to $407 million, with Yescarta sales down 14% to $332 million and Tecartus down 4% to $75 million. This decline is attributed to ongoing in- and out-of-class competition, posing challenges to Gilead's market share in this innovative but highly competitive segment.
Increased Operating Expenses: Selling, general and administrative (SG&A) expenses rose to $1.5 billion from $1.3 billion in the prior year. This increase was primarily driven by higher HIV promotional expenses and significant donations of equity securities, indicating rising costs associated with marketing and corporate social responsibility initiatives.
🔮 CEO / Management Guidance
CEO Daniel O’Day highlighted that Gilead has raised its full-year revenue guidance, reflecting the strong performance of its base business. He emphasized the company's commitment to building the strongest pipeline in its history through strategic acquisitions in oncology and inflammation. Gilead anticipates up to four potential product launches and five Phase 3 updates in 2026, positioning the company for sustained growth in both the near and long term.
💬 Key Quote
Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance." — Daniel O’Day, Chairman and Chief Executive Officer
🏢 About Gilead Sciences
Gilead Sciences (GILD) is a publicly listed company on the NASDAQ exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.
📈 Want to act on this insight?
Topics:
HIV Portfolio
Oncology Pipeline
Strategic Acquisitions
Financial Guidance
📁 More from Gilead Sciences
View all earnings summaries for Gilead Sciences →